Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-143-3p inhibitor is a chemically modified antisense oligonucleotide designed to specifically bind and inhibit the mature microRNA miR-143-3p. In preclinical research, miR-143-3p inhibitors are utilized to investigate the role of miR-143-3p in various pathological conditions, including benign prostatic hyperplasia (BPH), preeclampsia, and various cancers. By blocking miR-143-3p, these inhibitors prevent the downregulation of its target genes, thereby modulating cellular functions such as contractility, proliferation, and apoptosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-143-3p inhibitor.